Selected research
Industry Growth & Trends
Global Drugs based on Genetic Engineering Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Drugs based on Genetic Engineering market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Drugs based on Genetic Engineering is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Drugs based on Genetic Engineering market include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Drugs based on Genetic Engineering market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Drugs based on Genetic Engineering market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs based on Genetic Engineering market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs based on Genetic Engineering.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Drugs based on Genetic Engineering market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Drugs based on Genetic Engineering Market by Company
GenSci
Takeda
CSPC
3SBIO
Sandoz
Sanofi
Johnson & Johnson
Novo Nordisk
Merck
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Biogen
Bayer
Bristol-Myers Squibb
Amgen
AbbVie
Swedish Orphan Biovitrum
Organon Pharma
Drugs based on Genetic Engineering Segment by Type
Recombinant Growth Factor
Recombinant Coagulation Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Fusion Protein
Other
Drugs based on Genetic Engineering Segment by Application
Autoimmune Diseases
Cancers
Metabolic Disorders
Infectious Diseases
Drugs based on Genetic Engineering Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs based on Genetic Engineering market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs based on Genetic Engineering and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs based on Genetic Engineering.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Drugs based on Genetic Engineering companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Growth Factor
- Recombinant Coagulation Factor
- Recombinant Hormone
- Recombinant Interferon
- Recombinant Interleukin
- Fusion Protein
- Other
Applications
- Autoimmune Diseases
- Cancers
- Metabolic Disorders
- Infectious Diseases
Companies covered
- GenSci
- Takeda
- CSPC
- 3SBIO
- Sandoz
- Sanofi
- Johnson & Johnson
- Novo Nordisk
- Merck
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Biogen
- Bayer
- Bristol-Myers Squibb
- Amgen
- AbbVie
- Swedish Orphan Biovitrum
- Organon Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Drugs based on Genetic Engineering Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Drugs based on Genetic Engineering Market Size by Region (2021-2032)
- 1.4.1 Global Drugs based on Genetic Engineering Market Size by Region (2021-2026)
- 1.4.2 Global Drugs based on Genetic Engineering Market Size by Region (2027-2032)
- 1.5 Key Regions Drugs based on Genetic Engineering Market Size (2021-2032)
- 1.5.1 North America Drugs based on Genetic Engineering Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Drugs based on Genetic Engineering Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Drugs based on Genetic Engineering Market Size Growth Rate (2021-2032)
- 1.5.4 South America Drugs based on Genetic Engineering Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Drugs based on Genetic Engineering Market Size Growth Rate (2021-2032)
2 Drugs based on Genetic Engineering Market by Type
- 2.1 Type Introduction
- 2.1.1 Recombinant Growth Factor
- 2.1.2 Recombinant Coagulation Factor
- 2.1.3 Recombinant Hormone
- 2.1.4 Recombinant Interferon
- 2.1.5 Recombinant Interleukin
- 2.1.6 Fusion Protein
- 2.1.7 Other
- 2.2 Global Drugs based on Genetic Engineering Market Size by Type
- 2.2.1 Global Drugs based on Genetic Engineering Market Size Overview by Type (2021-2032)
- 2.2.2 Global Drugs based on Genetic Engineering Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Drugs based on Genetic Engineering Market Size Forecasted by Type (2027-2032)
- 2.3 Global Drugs based on Genetic Engineering Market Size by Regions
- 2.3.1 North America Drugs based on Genetic Engineering Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Drugs based on Genetic Engineering Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Drugs based on Genetic Engineering Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Drugs based on Genetic Engineering Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Drugs based on Genetic Engineering Market Size Breakdown by Type (2021-2026)
3 Drugs based on Genetic Engineering Market by Application
- 3.1 Type Introduction
- 3.1.1 Autoimmune Diseases
- 3.1.2 Cancers
- 3.1.3 Metabolic Disorders
- 3.1.4 Infectious Diseases
- 3.2 Global Drugs based on Genetic Engineering Market Size by Application
- 3.2.1 Global Drugs based on Genetic Engineering Market Size Overview by Application (2021-2032)
- 3.2.2 Global Drugs based on Genetic Engineering Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Drugs based on Genetic Engineering Market Size Forecasted by Application (2027-2032)
- 3.3 Global Drugs based on Genetic Engineering Market Size by Regions
- 3.3.1 North America Drugs based on Genetic Engineering Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Drugs based on Genetic Engineering Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Drugs based on Genetic Engineering Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Drugs based on Genetic Engineering Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Drugs based on Genetic Engineering Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Drugs based on Genetic Engineering Industry Trends
- 4.2 Drugs based on Genetic Engineering Industry Drivers
- 4.3 Drugs based on Genetic Engineering Industry Opportunities and Challenges
- 4.4 Drugs based on Genetic Engineering Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Drugs based on Genetic Engineering Revenue (2021-2026)
- 5.2 Global Drugs based on Genetic Engineering Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Drugs based on Genetic Engineering Key Company Headquarters & Area Served
- 5.4 Global Drugs based on Genetic Engineering Company, Product Type & Application
- 5.5 Global Drugs based on Genetic Engineering Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Drugs based on Genetic Engineering Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Drugs based on Genetic Engineering Players Market Share by Revenue in 2025
- 5.6.3 2025 Drugs based on Genetic Engineering Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 GenSci
- 6.1.1 GenSci Company Information
- 6.1.2 GenSci Business Overview
- 6.1.3 GenSci Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 GenSci Drugs based on Genetic Engineering Product Portfolio
- 6.1.5 GenSci Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Takeda Drugs based on Genetic Engineering Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 CSPC
- 6.3.1 CSPC Company Information
- 6.3.2 CSPC Business Overview
- 6.3.3 CSPC Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 CSPC Drugs based on Genetic Engineering Product Portfolio
- 6.3.5 CSPC Recent Developments
- 6.4 3SBIO
- 6.4.1 3SBIO Company Information
- 6.4.2 3SBIO Business Overview
- 6.4.3 3SBIO Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 3SBIO Drugs based on Genetic Engineering Product Portfolio
- 6.4.5 3SBIO Recent Developments
- 6.5 Sandoz
- 6.5.1 Sandoz Company Information
- 6.5.2 Sandoz Business Overview
- 6.5.3 Sandoz Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sandoz Drugs based on Genetic Engineering Product Portfolio
- 6.5.5 Sandoz Recent Developments
- 6.6 Sanofi
- 6.6.1 Sanofi Company Information
- 6.6.2 Sanofi Business Overview
- 6.6.3 Sanofi Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Sanofi Drugs based on Genetic Engineering Product Portfolio
- 6.6.5 Sanofi Recent Developments
- 6.7 Johnson & Johnson
- 6.7.1 Johnson & Johnson Company Information
- 6.7.2 Johnson & Johnson Business Overview
- 6.7.3 Johnson & Johnson Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Johnson & Johnson Drugs based on Genetic Engineering Product Portfolio
- 6.7.5 Johnson & Johnson Recent Developments
- 6.8 Novo Nordisk
- 6.8.1 Novo Nordisk Company Information
- 6.8.2 Novo Nordisk Business Overview
- 6.8.3 Novo Nordisk Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Novo Nordisk Drugs based on Genetic Engineering Product Portfolio
- 6.8.5 Novo Nordisk Recent Developments
- 6.9 Merck
- 6.9.1 Merck Company Information
- 6.9.2 Merck Business Overview
- 6.9.3 Merck Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Merck Drugs based on Genetic Engineering Product Portfolio
- 6.9.5 Merck Recent Developments
- 6.10 Roche
- 6.10.1 Roche Company Information
- 6.10.2 Roche Business Overview
- 6.10.3 Roche Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Roche Drugs based on Genetic Engineering Product Portfolio
- 6.10.5 Roche Recent Developments
- 6.11 Eli Lilly
- 6.11.1 Eli Lilly Company Information
- 6.11.2 Eli Lilly Business Overview
- 6.11.3 Eli Lilly Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Eli Lilly Drugs based on Genetic Engineering Product Portfolio
- 6.11.5 Eli Lilly Recent Developments
- 6.12 Pfizer
- 6.12.1 Pfizer Company Information
- 6.12.2 Pfizer Business Overview
- 6.12.3 Pfizer Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Pfizer Drugs based on Genetic Engineering Product Portfolio
- 6.12.5 Pfizer Recent Developments
- 6.13 GlaxoSmithKline
- 6.13.1 GlaxoSmithKline Company Information
- 6.13.2 GlaxoSmithKline Business Overview
- 6.13.3 GlaxoSmithKline Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 GlaxoSmithKline Drugs based on Genetic Engineering Product Portfolio
- 6.13.5 GlaxoSmithKline Recent Developments
- 6.14 Biogen
- 6.14.1 Biogen Company Information
- 6.14.2 Biogen Business Overview
- 6.14.3 Biogen Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Biogen Drugs based on Genetic Engineering Product Portfolio
- 6.14.5 Biogen Recent Developments
- 6.15 Bayer
- 6.15.1 Bayer Company Information
- 6.15.2 Bayer Business Overview
- 6.15.3 Bayer Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Bayer Drugs based on Genetic Engineering Product Portfolio
- 6.15.5 Bayer Recent Developments
- 6.16 Bristol-Myers Squibb
- 6.16.1 Bristol-Myers Squibb Company Information
- 6.16.2 Bristol-Myers Squibb Business Overview
- 6.16.3 Bristol-Myers Squibb Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Bristol-Myers Squibb Drugs based on Genetic Engineering Product Portfolio
- 6.16.5 Bristol-Myers Squibb Recent Developments
- 6.17 Amgen
- 6.17.1 Amgen Company Information
- 6.17.2 Amgen Business Overview
- 6.17.3 Amgen Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Amgen Drugs based on Genetic Engineering Product Portfolio
- 6.17.5 Amgen Recent Developments
- 6.18 AbbVie
- 6.18.1 AbbVie Company Information
- 6.18.2 AbbVie Business Overview
- 6.18.3 AbbVie Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 AbbVie Drugs based on Genetic Engineering Product Portfolio
- 6.18.5 AbbVie Recent Developments
- 6.19 Swedish Orphan Biovitrum
- 6.19.1 Swedish Orphan Biovitrum Company Information
- 6.19.2 Swedish Orphan Biovitrum Business Overview
- 6.19.3 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Product Portfolio
- 6.19.5 Swedish Orphan Biovitrum Recent Developments
- 6.20 Organon Pharma
- 6.20.1 Organon Pharma Company Information
- 6.20.2 Organon Pharma Business Overview
- 6.20.3 Organon Pharma Drugs based on Genetic Engineering Revenue, Global Share and Gross Margin (2021-2026)
- 6.20.4 Organon Pharma Drugs based on Genetic Engineering Product Portfolio
- 6.20.5 Organon Pharma Recent Developments
7 North America
- 7.1 North America Drugs based on Genetic Engineering Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Drugs based on Genetic Engineering Market Size by Country (2021-2026)
- 7.3 North America Drugs based on Genetic Engineering Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Drugs based on Genetic Engineering Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Drugs based on Genetic Engineering Market Size by Country (2021-2026)
- 8.3 Europe Drugs based on Genetic Engineering Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs based on Genetic Engineering Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Drugs based on Genetic Engineering Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Drugs based on Genetic Engineering Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Drugs based on Genetic Engineering Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Drugs based on Genetic Engineering Market Size by Country (2021-2026)
- 10.3 South America Drugs based on Genetic Engineering Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs based on Genetic Engineering Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Drugs based on Genetic Engineering Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Drugs based on Genetic Engineering Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst